How to Get Jardiance in Tennessee: Prescriptions, Telehealth, and Pharmacy Access

Empagliflozin, sold under the brand name Jardiance, is an oral SGLT2 (sodium-glucose cotransporter-2) inhibitor taken as a once-daily tablet in either 10 mg or 25 mg doses. The FDA has approved empagliflozin for four distinct uses: controlling blood sugar in type 2 diabetes, lowering the risk of cardiovascular death in patients with both type 2 diabetes and established heart disease, treating heart failure (whether the heart pumps weakly or normally), and slowing kidney disease progression when protein is present in urine, as documented in the current prescribing information. Within Tennessee, empagliflozin is readily accessible from licensed physicians and telehealth services. The primary obstacle is insurance coverage, as TennCare (Tennessee Medicaid), commercial insurers, and Medicare Part D each enforce their own distinct approval criteria for empagliflozin based on the patient's specific condition, and these requirements evolve periodically. Timely access to empagliflozin in Tennessee depends largely on adequate medical documentation rather than drug availability.

Direct answer. Empagliflozin (Jardiance) can be prescribed in Tennessee by a physician, an independently practicing nurse practitioner, or a physician assistant working under a collaborative agreement, either in person or through a telehealth visit, since it is not a controlled substance and does not require an in-person exam under federal telehealth rules. Prescribing typically requires a documented diagnosis (type 2 diabetes, heart failure, or CKD) plus recent kidney function testing, because prescribing information for the drug advises against starting it when estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73m². Coverage is the variable piece: as of this review, TennCare's own guidance should be checked directly for which indications it pays for, since Medicaid formularies are revised on a regular cycle and a diabetes-only diagnosis is treated differently from a heart failure or CKD diagnosis on many plans.

What Jardiance is approved for, and why that matters for access

Empagliflozin was first approved by the FDA in 2014 for glycemic control in type 2 diabetes. Later label expansions added reduction of cardiovascular death risk in adults with type 2 diabetes and established cardiovascular disease, heart failure across the ejection fraction spectrum, and chronic kidney disease with albuminuria, per its approved labeling. These four indications matter for Tennessee access because insurers frequently apply different prior authorization criteria to each one. A patient being treated for heart failure alone, with no diabetes diagnosis, is reviewed against different documentation requirements than a patient being treated for type 2 diabetes alone.

The underlying evidence for the cardiovascular and kidney indications comes from large randomized outcomes trials, including the EMPA-REG OUTCOME trial in patients with type 2 diabetes and existing cardiovascular disease, and the EMPA-KIDNEY trial in patients with chronic kidney disease with or without diabetes. Both trials reported reductions in cardiovascular death and in kidney disease progression compared with placebo. Readers who need the exact effect sizes (hazard ratios, confidence intervals) for a clinical or appeal-letter purpose should pull them from the trial's original publication or the FDA label rather than relying on secondhand figures, since precise numbers are easy to misquote and this draft has not independently re-verified every statistic against the primary paper.

The American Diabetes Association's Standards of Care recommends SGLT2 inhibitors for patients with type 2 diabetes who also have atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, independent of their A1c level [3]. That guideline is a major reason Tennessee prescribers now start Jardiance in patients whose diabetes is otherwise well controlled, when a qualifying comorbidity is present.

Tennessee has a diabetes prevalence above the national average according to CDC surveillance data, though the exact current percentage should be pulled from the CDC's National Diabetes Statistics Report rather than an outdated figure, since these reports are updated periodically [4].

Who can actually write the prescription in Tennessee

Any Tennessee-licensed prescriber with an active DEA registration and a valid prescribing relationship can write for Jardiance. That includes:

• Physicians (MD, DO), prescribing independently
• Nurse practitioners, who hold full independent practice and prescribing authority in Tennessee under state nursing board rules [5]
• Physician assistants, who prescribe under a collaborative practice agreement with a supervising physician, though that agreement does not require the physician to co-sign each individual prescription

Because empagliflozin is not a controlled substance, Tennessee prescribers are not bound by the same in-person examination requirement that applies to controlled substances under federal law. A synchronous video visit, or in some cases an asynchronous visit built around uploaded labs and a structured questionnaire, is generally sufficient to establish the prescribing relationship. Exact requirements vary by telehealth platform and by prescriber judgment, so confirm the specific visit format before booking.

What labs typically come before a first prescription

Tennessee prescribers generally want three pieces of information before starting empagliflozin:

A basic metabolic panel, to calculate eGFR from serum creatinine. The FDA label advises against initiating empagliflozin when eGFR is below 30 mL/min/1.73m², and clinical guidance from endocrinology societies notes that glucose-lowering efficacy declines meaningfully below an eGFR of roughly 45 [3].

A urine albumin-to-creatinine ratio (UACR), which identifies diabetic kidney disease and is part of the standard workup for the CKD indication specifically.

A recent hemoglobin A1c, which most commercial plans want documented for the type 2 diabetes indication, generally alongside evidence that metformin has already been tried or is not appropriate for the patient. Exact A1c thresholds and step-therapy rules are plan-specific and should be confirmed with the individual insurer rather than assumed from a general rule.

Some prescribers also order a urinalysis to rule out an active urinary tract infection before starting, since active infection is a relative contraindication to beginning an SGLT2 inhibitor.

Verification checklist: what is stable versus what changes

Some facts about Jardiance access in Tennessee are fixed by federal regulation or established clinical guidance and do not change often. Others are set by individual insurers, the state Medicaid program, or pharmacies, and can change month to month. Confusing the two is the most common source of outdated advice on this topic. Use this checklist before acting on any specific claim in this article or elsewhere.

If a claim in this article falls into the "volatile" half of this table, treat any specific number here as illustrative rather than current, and confirm it directly before making a coverage or purchasing decision.

How telehealth prescribing works in Tennessee

Telehealth prescribing of non-controlled medications, including empagliflozin, is generally permitted in Tennessee under state telehealth law. A typical visit follows this pattern:

1. An intake questionnaire covering diagnosis history, current medications, and allergies
2. Upload of recent labs (basic metabolic panel, A1c, UACR) if available
3. A video visit with a Tennessee-licensed prescriber
4. An electronic prescription sent to a pharmacy of your choice, or a request for mail order

If labs are not current, many telehealth platforms can issue a standing lab order so blood can be drawn locally before the prescribing visit happens. Turnaround from a completed visit to a filled prescription is usually measured in a small number of business days for local pharmacies and somewhat longer for mail order, though exact timing depends on the pharmacy and platform and should not be assumed to be same-day unless confirmed.

Coverage differs sharply by payer, and that is the real access question

TennCare. Tennessee's Medicaid program applies its own preferred drug list and prior authorization criteria to empagliflozin, and those criteria are reviewed periodically. Historically, coverage for heart failure and CKD indications has been broader than coverage for type 2 diabetes alone, but the exact current policy should be confirmed directly with TennCare rather than assumed from a prior year's rule. If your primary diagnosis is type 2 diabetes without a heart failure or CKD diagnosis, do not assume TennCare will cover Jardiance without checking current policy first.

Commercial insurance. Commercial plans operating in Tennessee generally place Jardiance on a non-preferred or specialty tier requiring prior authorization, with step therapy (a documented metformin trial or intolerance) common for the diabetes indication specifically. Criteria for the heart failure and CKD indications tend to be less restrictive because the supporting evidence and guideline recommendations for those uses are strong and less ambiguous. Specific formulary tier and prior authorization language vary by plan and change over time, so confirm with the individual insurer, not with a general summary.

Medicare Part D. Coverage varies by plan, and out-of-pocket cost depends heavily on which plan and which coverage phase (deductible, initial coverage, catastrophic) a patient is in during the year. Medicare's own published Part D resources are the accurate source for current plan-by-plan coverage.

Manufacturer assistance and cash price. Manufacturer copay cards can lower out-of-pocket cost for commercially insured patients but are not available to patients on federal programs (Medicare, Medicaid, TRICARE). Cash price without insurance varies by pharmacy and changes over time; a same-day price check at the dispensing pharmacy, or a pharmacy price-comparison tool, is more reliable than any fixed number quoted in an article.

Transferring an existing Jardiance prescription into Tennessee

Tennessee-licensed pharmacists can accept an electronic or faxed transfer of a non-controlled prescription from an out-of-state pharmacy, with the originating pharmacy voiding its remaining refills at the time of transfer, under standard pharmacy board rules. If you have refills remaining, you can generally call a Tennessee pharmacy with your prior pharmacy's name, phone number, and prescription number, and the pharmacists handle the transfer.

If no refills remain, you need a new prescription from a Tennessee-licensed provider. A telehealth visit is typically the fastest route, and bringing documentation of the prior prescription (a label photo or pharmacy printout) along with recent labs speeds the visit.

Compounded empagliflozin: when it applies and when it does not

Tennessee has licensed 503A compounding pharmacies that may prepare a patient-specific empagliflozin formulation, such as a liquid suspension, when a prescriber documents a clinical need the commercial tablet cannot meet, under the federal framework governing 503A compounding [10]. This applies to situations such as an inability to swallow tablets or a documented allergy to an inactive ingredient in the commercial product. It is not a general alternative to the FDA-approved tablet, and because commercially manufactured empagliflozin is not on the FDA's drug shortage list, the bar for medical necessity is higher than it would be for a shortage drug [10]. Compounded preparations are patient-specific, not stocked for general sale, and interstate shipping of 503A compounds is restricted.

If a prior authorization is denied

Tennessee law sets timelines for insurer review of prior authorization requests and for external independent review if an internal appeal is denied, with the Tennessee Department of Commerce and Insurance overseeing the external review process [11]. A denial appeal is generally strengthened by a letter of medical necessity that documents the relevant diagnosis, recent labs, and, where applicable, prior therapy trials. Citing the ADA Standards of Care recommendation for SGLT2 inhibitor use in patients with cardiovascular disease, heart failure, or CKD can support an appeal for those indications specifically [3]. While an appeal is pending, a short cash-pay fill or manufacturer savings program (where eligible) can bridge the gap, though neither substitutes for resolving the underlying coverage question.

What monitoring looks like after starting

Guideline-based follow-up after starting an SGLT2 inhibitor generally includes rechecking kidney function (eGFR) and UACR a few months after starting and then periodically thereafter [3]. Genital mycotic infection is the most commonly reported adverse effect in clinical trials. Rarer but more serious risks include euglycemic diabetic ketoacidosis, which can occur even with a normal blood glucose reading and is more likely during fasting, acute illness, or perioperative periods, and Fournier's gangrene, a rare but serious soft-tissue infection reported with this drug class. Prescribing information advises holding empagliflozin for a period before scheduled surgery because of ketoacidosis risk; confirm the specific interval and any individualized adjustment with the prescribing clinician rather than a general timeline. Anyone who develops nausea, vomiting, abdominal pain, unusual fatigue, or difficulty breathing while on empagliflozin, particularly around a period of fasting or illness, should seek urgent medical evaluation rather than waiting for a routine follow-up.

Evidence boundary

Established: empagliflozin's FDA-approved indications, its mechanism as an SGLT2 inhibitor, its renal function threshold for initiation, and the existence of independent NP prescribing authority and legal telehealth prescribing in Tennessee. Plausible but requiring current verification: the specific dollar amounts, tier placements, and step-therapy criteria used by any named insurer or TennCare at this moment, since payer policy changes on its own schedule and this article cannot certify today's rule. Not established here: individualized guidance on whether a specific patient should start empagliflozin, at what dose, or whether a particular plan will approve a particular request; those questions require the patient's own prescriber and the specific payer, not a general access guide.

Common questions

Do I need to see an endocrinologist to get Jardiance in Tennessee? No. A primary care physician, nurse practitioner, physician assistant, or a telehealth prescriber can start empagliflozin when appropriate. Endocrinology referral is more relevant for complex diabetes management than for initiating this specific medication.

Can I get Jardiance for heart failure without a diabetes diagnosis? Yes. The FDA has approved empagliflozin for heart failure with reduced and with preserved ejection fraction regardless of diabetes status, so a prescriber can write for it using a heart failure diagnosis alone.

Does TennCare cover Jardiance? It depends on the indication and on TennCare's current formulary, which is reviewed periodically. Confirm current coverage directly with TennCare before assuming an outcome.

Is telehealth prescribing of Jardiance actually legal in Tennessee? Yes, for non-controlled medications like empagliflozin, under state telehealth law, and a nurse practitioner with independent authority does not need a physician co-signature [5].

References

3. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes. https://diabetesjournals.org/care/issue/46/Supplement_1

4. Centers for Disease Control and Prevention. National Diabetes Statistics Report. https://www.cdc.gov/diabetes/data/statistics-report/index.html

5. Tennessee Board of Nursing. APRN scope of practice guidance. https://www.tn.gov/health/health-program-areas/health-professional-boards/nursing-board.html

6. U.S. Food and Drug Administration. Compounding laws and policies (Section 503A). https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

7. Tennessee Department of Commerce and Insurance. Prior authorization requirements for health insurance. https://www.tn.gov/commerce/insurance/health-insurance.html